| Dear Voornaam,
Last year, Cancer Research Horizons recognised Claire Lewis, cofounder of spinout BioActa with our Woman Entrepreneur of the Year award. Claire’s track record includes running a spin-out company, out-licensing multiple novel cancer therapeutics, and successfully collaborating with numerous commercial partners to develop new cancer drug candidates.
This year, I am delighted to call for nominations for the second Innovation & Entrepreneurship Awards, where we aim to recognise the many exceptional achievements of women innovators and entrepreneurs. I look forward to receiving nominations for women who have established businesses and set up transformative partnerships to accelerate scientific discoveries into novel treatments to benefit cancer patients.
Do not miss out on the chance to become the next Woman Entrepreneur of the Year and nominate yourself or a colleague by 10 January 2024.
Kind regards,
Iain Foulkes
Executive Director Research & Innovation
CEO Cancer Research Horizons
Cancer Research UK |
|
|---|
|
|---|
|
|
Funding & Research Opportunities |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
|
|
HERE’S WHY YOU SHOULD COME TO OUR WORKSHOP ON DRUG RESISTANCE Peter Weightman (University of Liverpool) and Alexis Barr (Imperial College London) are on the programme committee for our upcoming interdisciplinary workshop on tackling drug resistance in cancer.
Here’s what they’re looking forward to and why you should be excited too…
“This workshop is special because it’s addressing a really difficult problem—how to mitigate the effects of cancer resistance to therapies. As a physicist, I’m particularly excited to hear from colleagues dealing with pharmaceutical approaches because this might provide opportunities to develop models to characterise resistance or instruments to monitor it.” - Peter Weightman
“The workshop is a great opportunity to network and have those interdisciplinary conversations that will give fresh perspectives on generating bold ideas to try and prevent and combat drug resistance in cancer.” - Alexis Barr
Join us in York on 31 January 2024.
|
|
|---|
|
|---|
|
|
 TRELLIS TREE-BASED ANALYSIS REVEALS STROMAL REGULATION OF PATIENT-DERIVED ORGANOID DRUG RESPONSES Maria Ramos Zapatero, Alexander Tong, Christopher Tape and colleagues have published a paper in Cell on the highly scalable, tree-based treatment effect analysis method they developed called “Trellis” to compare patient and microenvironment-specific drug responses in thousands of single-cell datasets.
Their work addresses the inability of current screening technologies to reveal drug response mechanisms or how tumour microenvironment cells alter therapeutic performance.
Trellis single-cell screening revealed that on-target cell-cycle blockage and DNA-damage drug effects are common, even in chemorefractory patient-derived organoids. However, drug-induced apoptosis is rarer, patient-specific and aligns with cancer cell post-translational modification signalling. They found that cancer-associated fibroblasts can regulate patient-derived organoids plasticity- shifting proliferative colonic stem cells to slow-cycling revival stem colonic cells to protect cancer cells from chemotherapy.
|
|
|---|
|  AN ONCOGENIC PHENOSCAPE OF COLONIC STEM CELL POLARISATION Xiao Qin, Ferran Cardoso Rodriguez, Christopher Tape and colleagues performed a systematic single-cell analysis of 1,071 organoid cultures to functionally map how cell-intrinsic and -extrinsic cues co-regulate cell fate in colorectal cancer.
This analysis revealed that dysregulated cell-fate plasticity is a hallmark of colonic oncogenesis and that cells can rapidly traverse the colonic differentiation landscape via combinations of oncogenic and stromal signalling.
These findings have now been published in Cell with a Waddington-like landscape rendered for this paper appearing on the front cover of the issue.
|
|
|---|
|
|---|
|
|
 FIND YOUR INDUSTRY MENTORS WITH BROADENING HORIZONS The entrepreneurial programme Broadening Horizons offers in-person and virtual opportunities to learn, network and forge new collaborations in the health sector. You will hear from world-leading speakers and take part in mentoring trainings to develop the necessary skills and mindset for clinical translation.
The programme is funded by Cancer Research Horizons in partnership with Wellcome and Moving Ahead.
Submit your full application by 15 December to help us match you with the most fit mentors.
|
|
|---|
|  APPLY TO BECOME A CENTRE OF EXCELLENCE IN RADIATION RESEARCH Applications are now open for our Centre of Excellence in radiation research.
Through the second phase of funding, we will provide £20M of support to fund four to five Centres of Excellence for five years through to 2029. The Centres of Excellence will establish and maintain cutting-edge research infrastructure and build capacity by supporting early-career researcher training in radiation research.
Please contact the Centres and Institutes team at centres-institutes@cancer.org.uk for further details of the scope and eligibility for funding.
Apply before 20 February 2024.
|
|
|---|
|
|---|
|
|
| | | London, UK 17 January 2024 |
|
|---|
|
|---|
| | | Manchester, UK 27 February 2024 |
|
|---|
|
|---|
|
|
WHAT DID YOU THINK OF THIS EMAIL? We're always looking for ways to improve. Please give us your feedback by clicking below and leaving a comment. |
|
|---|
|
|---|
|
|
| Been forwarded this email?
Subscribe to our newsletter to stay up-to-date. |
|---|
| |
|---|
|
|
|
